Emerging properties of cannabinoid medicines in management of multiple sclerosis

Trends in Neurosciences

Volumn 28, Issue 5, 2005, Pages 272-276

  Pryce, Gareth ^a   Baker, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HUMAN; MULTIPLE SCLEROSIS; PAIN; PRIORITY JOURNAL; REVIEW; SPASTICITY; ANIMAL; DISEASE MANAGEMENT; METABOLISM;

ANIMALS; CANNABINOIDS; DISEASE MANAGEMENT; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CANNABINOID;

EID: 21744442759     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2005.03.006     Document Type: Review

References (62)

1. Mechoulam, R. (1986) The pharmacohistory of Cannabis saliva. In Cannabinoids as Therapeutic Agents (Mechoulam, R., ed.), pp. 1-19, CRC Press
2. Clark, A.J. et al. (2004) Patterns of cannabis use among patients with multiple sclerosis. Neurology 62, 2098-2100
3. Page, S.A. et al. (2003) Cannabis use as described by people with multiple sclerosis. Can. J. Neurol. Sci. 30, 201-205
4. Consroe, P. et al. (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38, 44-48
5. Compston, A. and Coles, A. (2002) Multiple sclerosis. Lancet 359, 1221-1231
6. Kurtzke, J.F. (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin. Microbiol. Rev. 6, 386-427
7. Confavreux, C. et al. (2000) Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343, 1430-1438
8. Ebers, G.C. (2004) Natural history of primary progressive multiple sclerosis. Mult. Scler. 10 (Suppl), S8-S13
9. Bjartmar, C. et al. (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48, 893-901
10. Bjartmar, C. et al. (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206, 165-171
11. Wujek, J.R. et al. (2002) Axon loss in the spinal cord determines permanent disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 61, 23-32
12. Barnes, M.P. et al. (2003) Spasticity in multiple sclerosis. Neurorehabil. Neural Repair 17, 66-70
13. Ivanhoe, C.B. and Reistetter, T.A. (2004) Spasticity: the misunderstood part of the upper motor neuron syndrome. Am. J. Phys. Med. Rehabil. 83 (10 Suppl.), S3-S9
14. Wilson, R.I. and Nicoll, R.A. (2002) Endocannabinoid signalling in the brain. Science 296, 678-682
15. Gaoni, Y. and Mechoulam, R. (1964) Isolation, structure and partial synthesis of an active component of hashish. J. Am. Chem. Soc. 86, 1646-1647
16. Matsuda, L.A. et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
17. Hewlett, A.C. et al. (2002) International Union of Pharmacology: XXVII, classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202
18. Munro, S. et al. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65
19. Hewlett, A.C. and Shim, J-Y. (2004) Cannabinoid receptors and signal transduction. In Cannabinoids (Di Marzo, V., ed.), pp. 84-97, Landes Bioscience
20. Devane, W.A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949
21. Mechoulam, R. et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 89-90
22. Cravatt, B.F. et al. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87
23. Dinh, T.P. et al. (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 99, 10819-10824
24. Baker, D. et al. (2003) Therapeutic potential of cannabis. Lancet Neurol. 2, 291-298
25. 2 receptors. Pharmacol. Ther. 74, 129-180
26. Kumar, R.N. et al. (2001) Pharmacological actions and therapeutic uses of cannabinoids. Anaesthesia 56, 1059-1068
27. Grotenhermen, F. (2004) Pharmacology of cannabinoids. Neuroendocrinol. Lett. 25, 14-23
28. Lyman, W.D. et al. (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 73-81
29. Wirguin, I. et al. (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28, 209-214
30. Bisogno, T. et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J. Pharmacol. 134, 845-852
31. Baker, D. et al. (2001) Endocannabinoids control Spasticity in a multiple sclerosis model. FASEB J. 15, 300-302
32. Baker, D. et al. (2000) Cannabinoids control Spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87
33. Hampson, A.J. et al. (2000) Neuroprotective antioxidants from marijuana. Ann. New York Acad. Sci. 899, 274-282
34. Malfait, A.M. et al. (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 97, 9561-9566
35. Pertwee, R.G. (2004) The pharmacology and therapeutic potential of cannabidiol. In Cannabinoids (Di Marzo, V., ed.), pp. 32-83, Landes Bioscience
36. 9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 28, 172-177
37. Baker, D. and Pryce, G. (2004) The potential role of the endocannabinoid system in the control of multiple sclerosis. Curr. Med. Chem. 4, 195-202
38. Arevalo-Martin, A. et al. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23, 2511-2516
39. 9- tetrahydrocannabinol necessary for all its effects? J. Pharm. Pharmacol. 55, 1687-1694
40. 1 and FAAH inhibitors in cannabinoid gene knockout mice. Symposium on the Cannabinoids, Paestum, (It.) International Cannabinoid Research Society, abstract 41 (http://cannabinoidsociety. org/symposium.2004/2004.symp.frontpage. html)
41. Pryce, G. et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202
42. van Oosten, B.W. et al. (2004) Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult. Scler. 10, 330-331
43. Pertwee, R.G. (2002) Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95, 165-174
44. Killestein, J. et al. (2002) Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 58, 1404-1407
45. Vaney, C. et al. (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 10, 417-424
46. Zajicek, J. et al. (2003) Cannabinoids for the treatment of other symptoms related to multiple sclerosis (CAMS study): multicentre, randomized, placebo-controlled trial. Lancet 362, 1517-1526
47. Huestis, M.A. et al. (1992) Blood cannabinoids; I. absorption of THC and formation of 11-OH-THC and THC-COOH during and after smoking marijuana. J. Anal. Toxicol. 16, 228-235
48. Grotenhermen, F. (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42, 327-360
49. Wall, M.E. et al. (1983) Metabolism, disposition and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin. Pharmacol. Ther. 34, 352-363
50. Ohlsson, A. et al. (1980) Plasma delta-9 tetrahydrcannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28, 409-416
51. Timpone, J.C. et al. (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res. Hum. Retroviruses 13, 305-315
52. Fox, P. et al. (2004) The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 62, 1105-1109
53. Ashworth, B. (1964) Preliminary trial of carisopodol in multiple sclerosis. Practitioner 192, 540-542
54. Shakespeare, D.T. et al. (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD001332
55. Svendsen, K.B. et al. (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med. J. 329, 253
56. Zajicek, J. (2004) The cannabinoids in MS study - final results from 12 months follow-up. Mult. Scler. l0(Suppl), S115
57. Guy, G.W. and Flint, M.E. (2000) A phase one study of sublingual cannabis based medicinal extracts. Symposium on the Cannabinoids. Burlington (VT), International Cannabinoid Research Society, abstract 115 (http:// cannabinoidsociety.org/HTML/ICRS.2000. symposium.html)
58. Wade, D.T. et al. (2004) Do cannabis based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A doubleblind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10, 434-441
59. Brady, C.M. et al. (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10, 425-433
60. Notcutt, W. et al. (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59, 440-452
61. Williams, S.J. et al. (1976) Bronchdilator effect of delta 1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 31, 720-723
62. Lichtman, A.H. et al. (2000) Pharmacological evaluation of aerosolized cannabinoids in mice. Eur. J. Pharmacol. 399, 141-149